- 作者: Chih-Pin Chuu, John M Kokontis, Richard A Hiipakka, Junichi Fukuchi, Hui-Ping Lin, Ching-Yu Lin, Chiech Huo, Liang-Cheng Su
- 作者服務機構: Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan, R.O.C.
- 中文摘要: --
- 英文摘要:
Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men
in Western countries. While surgery is often successful for organ-confined prostate
cancer, androgen ablation therapy is the primary treatment for metastatic prostate
cancer. However, this therapy is associated with several undesired side-effects,
including increased risk of cardiovascular diseases. Shortening the period of androgen
ablation therapy may benefit prostate cancer patients. Intermittent Androgen
Deprivation therapy improves quality of life, reduces toxicity and medical costs, and
delays disease progression in some patients. Cell culture and xenograft studies using
androgen receptor (AR)-positive castration-resistant human prostate cancers cells
(LNCaP, ARCaP, and PC-3 cells over-expressing AR) suggest that androgens may
suppress the growth of AR-rich prostate cancer cells. Androgens cause growth
inhibition and G1 cell cycle arrest in these cells by regulating c-Myc, Skp2, and
p27Kip via AR. Higher dosages of testosterone cause greater growth inhibition of
relapsed tumors. Manipulating androgen/AR signaling may therefore be a potential
therapy for AR-positive advanced prostate cancer. - 中文關鍵字: --
- 英文關鍵字: --